| Literature DB >> 31209568 |
Rachel Stiner1,2, Michael Alexander1,2,3, Guangyang Liu1,2,3,4, Wenbin Liao4, Yongjun Liu1,3,4,5, Jingxia Yu1,2,3,4, Egest J Pone1,3,5,6,7, Weian Zhao1,3,4,5,6,7, Jonathan R T Lakey8,9,10,11.
Abstract
In recent years, human umbilical cord blood has emerged as a rich source of stem, stromal and immune cells for cell-based therapy. Among the stem cells from umbilical cord blood, CD45+ multipotent stem cells and CD90+ mesenchymal stem cells have the potential to treat type I diabetes mellitus (T1DM), to correct autoimmune dysfunction and replenish β-cell numbers and function. In this review, we compare the general characteristics of umbilical cord blood-derived multipotent stem cells (UCB-SCs) and umbilical cord blood-derived mesenchymal stem cells (UCB-MSCs) and introduce their applications in T1DM. Although there are some differences in surface marker expression between UCB-SCs and UCB-MSCs, the two cell types display similar functions such as suppressing function of stimulated lymphocytes and imparting differentiation potential to insulin-producing cells (IPCs) in the setting of low immunogenicity, thereby providing a promising and safe approach for T1DM therapy.Entities:
Keywords: Immunomodulation; Insulin-producing cells; Mesenchymal stem cells; Multipotent stem cells; Type 1 diabetes mellitus; Umbilical cord blood
Mesh：
Substances：
Year: 2019 PMID： 31209568 DOI： 10.1007/s00441-019-03046-2
Source DB: PubMed Journal: Cell Tissue Res ISSN： 0302-766X Impact factor: 5.249